Michael Gelband’s Charles River Laboratories CRL Stock Holding History

Michael Gelband’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,469	Closed	-$2.5M	–	1647
2026 Q1	$2.5M	Buy	+14,469	New	+$2.68M	0.02%	698
2025 Q4	–	Sell	-49,700	Closed	-$7.78M	–	1634
2025 Q3	$7.78M	Buy	+49,700	New	+$7.89M	0.08%	267
2024 Q4	–	Sell	-1,979	Closed	-$390K	–	1606
2024 Q3	$390K	Buy	+1,979	New	+$411K	﹤0.01%	1282
2024 Q1	–	Sell	-38,838	Closed	-$9.18M	–	1569
2023 Q4	$9.18M	Sell	38,838 -26,296	-40%	-$5.17M	0.06%	218
2023 Q3	$12.8M	Buy	65,134 +50,798	+354%	+$10.4M	0.12%	178
2023 Q2	$3.01M	Sell	14,336 -45,754	-76%	-$9.1M	0.02%	648
2023 Q1	$12.1M	Buy	60,090 +52,271	+669%	+$11.8M	0.1%	220
2022 Q4	$1.7M	Buy	+7,819	New	+$1.71M	0.02%	720
2022 Q1	–	Sell	-2,997	Closed	-$1.13M	–	2265
2021 Q4	$1.13M	Buy	+2,997	New	+$1.16M	0.01%	1008
2021 Q2	–	Sell	-96,183	Closed	-$27.9M	–	2420
2021 Q1	$27.9M	Buy	96,183 +84,720	+739%	+$23.5M	0.41%	27
2020 Q4	$2.86M	Sell	11,463 -49,620	-81%	-$11.8M	0.03%	413
2020 Q3	$13.8M	Buy	+61,083	New	+$12.7M	0.28%	50
2019 Q4	–	Sell	-1,700	Closed	-$225K	–	1584
2019 Q3	$225K	Buy	+1,700	New	+$228K	0.01%	1056

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Michael Gelband's CRL Position: Q2 2026 in Review

Michael Gelband sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 14,469 shares — an estimated $2.5M sold.

Michael Gelband first reported a position in CRL in Q3 2019 and held it in 13 quarters. The position peaked at $27.9M in Q1 2021. 563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Michael Gelband reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 14,469 Charles River Laboratories shares in Q2 2026, an estimated $2.5M.
Michael Gelband first reported a position in Charles River Laboratories in Q3 2019 and held it in 13 quarters.
Michael Gelband's Charles River Laboratories position peaked at $27.9M in Q1 2021.
563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.